Cacipliq 20

Patients with non-healing leg ulcers due to severe limb ischemia and who cannot or no longer undergo vascular surgery, have high morbidity and amputation risks.

A device derived from a technology of water soluble engineered biodegradable nano-polymers mimicking heparan sulphates, produced promising results in preclinical models of chronic wounds.

We studied 14 chronic lower-extremity ulcers in 12 patients (median age, 71) TcPO 2 <30 mmHg and ABPI<0.5. At baseline, mean ulcer surface area and duration were 14.15 cm 2 and 7 months respectively. The device was used twice a week and perfectly tolerated.

After 4 weeks ulcer size reduction was 35% (p<0.001) (primary outcome). Increasing to 53% (p<0.001) at 8 weeks as 5 ulcers healed. Pain relief was also noted. RGTA (ReGeneraTing Agents) treatment was prolonged for 6 patients the third months and 2 healed (total 58% patients healed). Follow up for 9 patients indicated that 8 were alive at 12 months, with no ulcer reopening nor amputation nor death linked to treated ulcers.

Matrix protection therapy induced significant ulcer healing to full and stable closure in patients with severe ischemia for whom no other treatment options were available. This unique, simple to use and promising technology provides a new opportunity for unmet therapeutic needs.

The aim of this study was to determine whether a skin-specific bioengineered regenerating agent (RGTA) heparan sulphate mimetic (Cacipliq 20) improves chronic wound healing.
The design of this article is a prospective within-subject study. The setting was an urban hospital. Patients were 16 African-American individuals (mean age 42 years) with 22 wounds (mean duration 2.5 years) because of either pressure, diabetic, vascular or burn wounds.
Two participants each were lost to follow-up or removed because of poor compliance, resulting in 18 wounds analysed. Sterile gauze was soaked with Cacipliq 20 saline solution, placed on the wound for 5 min, then removed twice weekly for 4 weeks. Wounds were otherwise treated according to the standard of care.
Twenty-two percent of wounds fully healed during the treatment period. Wounds showed a 15.2-18.1% decrease in wound size as measured by the vision engineering research group (VERG) digital wound measurement system and total PUSH scores, respectively, at 4 weeks (P = 0.014 and P = 0.003).
At 8 weeks there was an 18-26% reduction in wound size (P = 0.04) in the remaining patients. Wound-related pain measured by the visual analogue pain scale and the wound pain scale declined 60% (P = 0.024) and 70% (P = 0.001), respectively. Patient and clinician satisfaction remained positive throughout the treatment period.
It is concluded that treatment with Cacipliq 20 significantly improved wound-related pain and may facilitate wound healing. Patient and clinician satisfaction remained high throughout the trial.

We evaluated whether matrix protection therapy by Cacipliq 20® promotes healing of chronic lower extremity wounds in diabetic patients.
Ten diabetic patients with non-infected chronic skin wounds and with no evidence of healing were included. Cacipliq 20® was applied topically twice a week for 5 minutes for up to 10 weeks. Wound surface area was measured at baseline then weekly during treatment. Wound closure, defined as complete reepithelialization, was the primary endpoint.
Mean wound surface area decreased by 25% within the first week (p=0.021 vs. baseline) and by 47% after 4 weeks (p=0.001 vs. baseline). After 10 weeks, the wound was closed in 6 of the 10 patients and decreased over 80% in the other patients. Subsequently, the none healed patients returned to standard care. Six months later, complete wound healing was noted in one additional patient and no further change in the remaining 3 patients. Two patients were again treated with Cacipliq 20® for one month: one healed, the other improved again by 50%.
Nine months later, closed ulcers did not re-open. No evidence of intolerance to Cacipliq 20® was noted. Matrix protection therapy holds considerable promise for healing chronic refractory foot wounds in diabetic patients.

A novel heparan sulfate glycosaminoglycan mimetic product for local application to promote wound healing (Cacipliq 20) has recently become available.
It is a biophysical therapeutic product comprising a polysaccharide as an innovative biomaterial to accomplish mechanical tissue engineering and skin regeneration in the site of ulceration.
We present a series of 12 patients with type 2 diabetes (4 men and 8 women; age 53-87 years; diabetes duration 8-25 years) having chronic resistance to therapy for foot and lower extremity ulcerations.
Cacipliq 20 was locally applied twice per week after careful debridement. Complete ulcer healing was accomplished in all patients after a mean treatment duration of 4.92 months (range = 2-12 months). The product was very well tolerated.
In conclusion, these results, although preliminary, are encouraging and suggest adequate efficacy and safety of the new product in difficult-to-heal foot and lower extremity ulcerations in type 2 diabetes.

Cacipliq 20® was used to accelerate the healing process and stimulate the viability of flaps and skin grafts, thereby improving amputation outcomes.

An excellent range of motion was achieved with hardly any contracture or scarring.

Pain relief and reduced sensitivity was noted, while healing of bone and tendon also improved, resulting in functional recovery.